Monoclonal Antibodies in Treating Chronic Spontaneous Urticaria: New Drugs for an Old Disease

Background: H1-antihistamines (H1AH) represent the current mainstay of treatment for chronic spontaneous urticaria (CSU). However, the response to H1AH is often unsatisfactory, even with increased doses. Therefore, guidelines recommend the use of omalizumab as an add-on treatment in refractory CSU....

Descripción completa

Detalles Bibliográficos
Autores principales: Manti, Sara, Giallongo, Alessandro, Papale, Maria, Parisi, Giuseppe Fabio, Leonardi, Salvatore
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9369449/
https://www.ncbi.nlm.nih.gov/pubmed/35956071
http://dx.doi.org/10.3390/jcm11154453

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9369449/
https://www.ncbi.nlm.nih.gov/pubmed/35956071
http://dx.doi.org/10.3390/jcm11154453

Ejemplares similares